Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALDOXAN D-CHANGE in routine clinical practice for major depressive episode
2008-008220-32Phase 4Completed
- Sponsor
- Eutherapie
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Eutherapie. Primary endpoint: Composite treatment response. Started Mar 2009; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-008220-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008220-32.